Showing results (91-100 of 219) with videos related to
Sort By:
Pageof 22
Gynecologic Oncology Reports|June 23, 2016
Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tractMaria B Schiavone, Vance Broach, Alexander N Shoushtari, et al.Cancer Chemotherapy and Pharmacology|March 5, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trialMichael S Gordon, Richard D Carvajal, Alexander Spira, et al.Investigational New Drugs|June 5, 2012
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumorsGary K Schwartz, Richard D Carvajal, Rachel Midgley, et al.NPJ Genomic Medicine|August 17, 2021
Multiregional genetic evolution of metastatic uveal melanomaDaniel A Rodriguez, Jessica Yang, Michael A Durante, et al.Plos One|July 17, 2025
Skin transcriptomics of invasive Coqui frogs: stress responses, parasite signatures, and antimicrobial peptidesRandy Ortiz, Leeann C Dabydeen, Carolyn Kosinski, et al.The Oncologist|May 13, 2015
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective ReviewDouglas B Johnson, Chengwei Peng, Richard G Abramson, et al.Cancer Research|March 20, 2019
Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal MelanomaGrazia Ambrosini, Catherine Do, Benjamin Tycko, et al.Head & Neck|April 5, 2016
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography responseRobert M Samstein, Richard D Carvajal, Michael A Postow, et al.Journal for Immunotherapy of Cancer|April 21, 2016
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoidKristen M Beck, Joanna Dong, Larisa J Geskin, et al.Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.Pageof 22